Sentences with phrase «outcomes results reported»

Our coaching protocol is generating positive outcomes results reported in peer - reviewed scientific journals.

The coaching protocol, featured in the Manual, is generating positive outcomes results reported in peer - reviewed scientific journals.

Not exact matches

Actual results or outcomes may differ materially from those implied by the forward - looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10 - K and our other reports filed with the Securities and Exchange Commission.

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

They're in the news over speculation that «fake news» spread via Facebook posts could have influenced the election outcome, and over Google's high placement of a search result reporting wrongly that Donald Trump got more popular votes than Hillary Clinton.

And now that the time for revisionist history has arrived, and strategists no longer have to serve a political agenda and scare investors and traders into voting with their wallets, the research reports calling for precisely the outcome that we expected are coming in fast and furious, starting with none other than Goldman, whose chief strategist David Kostin issued a note overnight in which he says that «the equity market response to the election result will be limited» and adds that «our year - end 2016 price target for the S&P 500 remains 2100, roughly 2 % below the current level of 2140.»

In addition to factors previously disclosed in Tesla's and SolarCity's reports filed with the U.S. Securities and Exchange Commission (the «SEC») and those identified elsewhere in this document, the following factors, among others, could cause actual results to differ materially from forward - looking statements and historical performance: the ability to obtain regulatory approvals and meet other closing conditions to the transaction, including requisite approval by Tesla and SolarCity stockholders, on a timely basis or at all; delay in closing the transaction; the ultimate outcome and results of integrating the operations of Tesla and SolarCity and the ultimate ability to realize synergies and other benefits; business disruption following the transaction; the availability and access, in general, of funds to meet debt obligations and to fund ongoing operations and necessary capital expenditures; and the ability to comply with all covenants in the indentures and credit facilities of Tesla and SolarCity, any violation of which, if not cured in a timely manner, could trigger a default of other obligations under cross-default provisions.

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

Actual results may vary materially from those expressed or implied by forward - looking statements based on a number of factors, including, without limitation: (1) risks related to the consummation of the Merger, including the risks that (a) the Merger may not be consummated within the anticipated time period, or at all, (b) the parties may fail to obtain shareholder approval of the Merger Agreement, (c) the parties may fail to secure the termination or expiration of any waiting period applicable under the HSR Act, (d) other conditions to the consummation of the Merger under the Merger Agreement may not be satisfied, (e) all or part of Arby's financing may not become available, and (f) the significant limitations on remedies contained in the Merger Agreement may limit or entirely prevent BWW from specifically enforcing Arby's obligations under the Merger Agreement or recovering damages for any breach by Arby's; (2) the effects that any termination of the Merger Agreement may have on BWW or its business, including the risks that (a) BWW's stock price may decline significantly if the Merger is not completed, (b) the Merger Agreement may be terminated in circumstances requiring BWW to pay Arby's a termination fee of $ 74 million, or (c) the circumstances of the termination, including the possible imposition of a 12 - month tail period during which the termination fee could be payable upon certain subsequent transactions, may have a chilling effect on alternatives to the Merger; (3) the effects that the announcement or pendency of the Merger may have on BWW and its business, including the risks that as a result (a) BWW's business, operating results or stock price may suffer, (b) BWW's current plans and operations may be disrupted, (c) BWW's ability to retain or recruit key employees may be adversely affected, (d) BWW's business relationships (including, customers, franchisees and suppliers) may be adversely affected, or (e) BWW's management's or employees» attention may be diverted from other important matters; (4) the effect of limitations that the Merger Agreement places on BWW's ability to operate its business, return capital to shareholders or engage in alternative transactions; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings, including any such proceedings related to the Merger and instituted against BWW and others; (6) the risk that the Merger and related transactions may involve unexpected costs, liabilities or delays; (7) other economic, business, competitive, legal, regulatory, and / or tax factors; and (8) other factors described under the heading «Risk Factors» in Part I, Item 1A of BWW's Annual Report on Form 10 - K for the fiscal year ended December 25, 2016, as updated or supplemented by subsequent reports that BWW has filed or files with the SEC.

# 5 shows where you confirm whether you won or lost your trade - just click the relevant button # 6 shows how many users reported trading the signal # 7 shows how many of those also reported their result # 8 shows the final outcome for all reported results

Not just that, you can watch as people report the outcome of the trade they took... and this all happens in REAL - TIME... as other traders in the Binary Matrix Pro community are reporting their actions and results.

This report draws together the results of each ecological indicator that is monitored and evaluated to inform an integrated Basin - scale assessment of the outcomes of Commonwealth environmental water in the first year of the LTIM Project.

A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward - looking statements, including but not limited to, (1) our ability to open new restaurants and food and beverage locations in current and additional markets, grow and manage growth profitably, maintain relationships with suppliers and obtain adequate supply of products and retain our key employees; (2) factors beyond our control that affect the number and timing of new restaurant openings, including weather conditions and factors under the control of landlords, contractors and regulatory and / or licensing authorities; (3) changes in applicable laws or regulations; (4) the possibility that the Company may be adversely affected by other economic, business, and / or competitive factors; and (5) other risks and uncertainties indicated from time to time in our filings with the SEC, including our Annual Report on Form 10 - K filed on March 30, 2016 and our Quarterly Report on Form 10 - Q filed on August 15, 2016.

Infact, there has been a report that has gone viral on the Football Social Media that, whatever be the outcome of the result that will emanate from the Bridge today's afternoon.

This is an important question, since it may be that some of the positive outcomes reported from fathers» leave - use (see below) may result from more advantaged fathers taking leave in the first place.

Research on the impact of depression on home visiting outcomes is mixed with some studies reporting negative results while others suggesting that depressed mothers may benefit from these programs.

Key results: Review authors found that full - term babies fed formula milk supplemented with LCPUFA did not have better outcomes than were reported for full - term babies fed formula milk without LCPUFA.

Only one trial reported the following outcomes: mean number of antenatal visits, perceptions of control, breastfeeding on discharge and postpartum depression and so results were not included in a meta - analysis.

All outcomes stated in the methods section were adequately reported in the results in 13 studies (Begley 2011; Biro 2000; Flint 1989; Harvey 1996; Hicks 2003; Homer 2001; Kenny 1994; MacVicar 1993; McLachlan 2012; North Stafford 2000; Rowley 1995; Turnbull 1996; Waldenstrom 2001).

On the basis of the distribution of the outcome variables and to aid with the interpretation of results, we dichotomized the positive parenting behaviors for fathers reporting these activities ≥ 3 days / week versus 2 or fewer days a week.

high risk of bias (where not all the study's prespecified outcomes have been reported; one or more reported primary outcomes were not prespecified; outcomes of interest are reported incompletely and so can not be used; study fails to include results of a key outcome that would have been expected to have been reported);

«Our results suggest that breastfeeding duration is independently associated with better educational outcomes in middle childhood, especially for boys,» reported Wendy H. Oddy, associate professor at the Telethon Institute for Child Health Research and University of Western Australia, and colleagues.

Breastfeeding was not reported as an outcome in the protocol, but was included as a primary outcome in the results paper.

This study is a sub-sample of results from a larger study and the outcomes reported in the trial registration document are not reported in this study, However, the full study results have not yet been published to be able to judge this outcome.

low risk of bias (where it was clear that all outcomes stated in the methods section were adequately reported or explained in results);

While the EIU report expects the results to be close and warned that the «outcome is not a foregone conclusion», it revealed that the NPP needs to maintain internal unity and reach out beyond its strongholds.

Each week, Monday through Friday, we reported three - day and five - day results for each of the three turnout models, thus generating six different outcomes daily.

Then they reported the results and statistical analysis no matter what the outcome,» Bohannon wrote.

Researchers report that the only substantial difference in safety outcomes between the placebo and bococizumab groups was injection site reactions, which is also the result of the immunologic response in some patients.

Funded by a $ 12 million grant, the FORCE - TJR research program has developed a national database of surgical results and patient - reported outcomes from more than 30,000 patients.

The results of the most extensive international study of the characteristics and outcomes of older emergency patients to be reported to date were published online in Annals of Emergency Medicine.

Stitziel and his colleagues pointed out that this question will be addressed later this month with the reporting of results from a large clinical trial called IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE - IT).

«Considering both the negative effects and the positive outcomes that respondents sometimes reported, the survey results confirm our view that neither users nor researchers can be cavalier about the risks associated with psilocybin,» says Roland Griffiths, Ph.D., a psychopharmacologist and professor of psychiatry and behavioral sciences and neurosciences at the Johns Hopkins University School of Medicine.

«Outcomes that are novel, or eye - catching are generally seen as more attractive and competitive than those that are null or ambiguous,» putting researchers under much career pressure to produce attractive results, says Chris Chambers, a cognitive neuroscientist at Cardiff University in the United Kingdom who became one of the founders of the Registered Reports concept a couple of years ago, in the Royal Society's announcement.

«STS public reporting uses detailed clinical registry data and outcomes that have been risk adjusted, meaning that the results take into account the condition of the patient at the time of surgery and whether or not there were other health problems, such as diabetes.»

Those results, reported in a 2015 New England Journal paper, found similar outcomes for both strategies in terms of the incidence of future cardiovascular events.

Those classes of products with higher than average reports of serious health outcomes were: baby, unclassified product classes, personal cleanliness, hair care and hair coloring products, according to the results.

«Our results suggest that the use of these small, relatively inexpensive devices is associated with significant increases in physical activity and improvements in some key health outcomes, at least in the short term,» internist Dena Bravata of Stanford University and her colleagues report in the Journal of the American Medical Association.

A recent study from the Thai - Myanmar border highlights the severe and previously under - reported adverse impact of readily treatable tropical rickettsial illnesses, notably scrub typhus and murine typhus, on pregnancy outcomes, finding that more than one third of affected pregnancies resulted either in stillbirth or premature and / or low birth weight babies.

Gill Clarke, vice chair of the UK Council for Graduate Education, presented the results of another HEFCE - funded report, «International comparisons in postgraduate education: quality, access and employment outcomes.»

The investigators noted that it's unclear whether medication errors resulting in serious outcomes are truly infrequent or are under - reported due to the difficulty in ascertaining them.

Overall, more than a quarter of working Americans (27 percent) reported at least one negative outcome as a result of political discussions at work during this election season.

Academic journals are increasingly asking authors to use transparent reporting practices to «trust, but verify» that outcomes are not being reported in a biased way and to enable other researchers to reproduce the results.

If the results of that evaluation confirm the results reported in our current paper, we will have made one of the strongest statements ever that mental health matters, not just for emotional health but for educational outcomes as well.»

The outcome was relayed to player B, who then privately rolled and reported the results as well.

Table 4 reports the results of 4 different logistic regression models with the presence of dementia as the outcome variable, using pooled 2000 and 2012 data.

deCODE's actual results could differ materially from those anticipated in the forward - looking statements as a result of risks and uncertainties, including, without limitation, (1) the impact of the announcement of its bankruptcy filing on deCODE's operations; (2) the ability of deCODE to maintain sufficient debtor - in - possession financing to fund its operations and the expenses of the Chapter 11 proceeding; (3) the ability of deCODE to obtain court approval of its motions in the Chapter 11 proceeding; (4) the outcome and timing of the proposed sale of deCODE's assets, including deCODE's ability to close a transaction with SagaInvestments, LLC or any other purchaser; (5) the uncertainty associated with motions by third parties in the bankruptcy proceeding; (6) deCODE's ability to obtain and maintain normal terms with vendors and service providers and contracts that are critical to its operation; and (7) other risks identified in deCODE's filings with the Securities and Exchange Commission, including, without limitation, the risk factors identified in our most recent Annual Report on Form 10 - K and any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10 - Q or Current Reports on Form 8 - K.

All research results, reports, and the outcomes of our meetings and programs will be made broadly available through publications and over the World Wide Web.

Scientific contributions include publication of the first randomized trials to assess the impact of common complex genetic risk markers, empirically measuring the outcomes of DTC genetic testing, design of a variant classification pipeline and single page summary for reporting clinical results of whole genome sequencing.